Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918384 | 1.00 | IDO1 (0.50) | IDO1PPARGPPARALTA4HAR | |
| SCHEMBL875568 | 0.88 | IDO1 (0.48) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL29918301 | 0.88 | IDO1 (0.48) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL877311 | 0.86 | PPARG (0.46) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL875588 | 0.86 | IDO1 (0.51) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL18235655 | 0.85 | AR (0.52) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL17884222 | 0.85 | AR (0.52) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL18235653 | 0.85 | PLA2G7 (0.46) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL9104268 | 0.84 | IDO1 (0.50) | IDO1PPARGPPARAARPLA2G7 | |
| SCHEMBL9104262 | 0.84 | IDO1 (0.50) | IDO1PPARGPPARAARPLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-3239135-B1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-08-15 | — | — | US | disclosed |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-07 | — | — | US | disclosed |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-07 | — | — | US | disclosed |
| US-20180009766-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-01-11 | — | — | US | disclosed |
| EP-3239135-A1 | PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-11-01 | — | — | EP | disclosed |
| EP-2948452-B1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787422-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | IDO1 511/4885PPARG 590/4885PPARA 313/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | IDO1 2560/4885PPARG 679/4885PPARA 484/4885 |
| US-10280146-B2 | Pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof | PLA2G12B, PLA2G1B, PLA2G4A | IDO1 511/4885PPARG 590/4885PPARA 313/4885 |
| US-20180009766-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | IDO1 511/4885PPARG 590/4885PPARA 313/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | IDO1 1563/4885PPARG 558/4885PPARA 372/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | IDO1 2760/4885PPARG 576/4885PPARA 346/4885 |
| US-20190248751-A1 | Pyrimidone Compounds Used as Lp-PLA2 Inhibitors and Pharmaceutical Compositions Thereof | PLA2G12B, PLA2G1B, PLA2G4A | IDO1 511/4885PPARG 590/4885PPARA 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.